Kudos on wanting to educate yourself on the matter. Funny though, how it's ok to reference and quote an article written by a trans activist...... but it's somehow naive to reference and quote an article written by a religious objector. Seems "double-standardish" to me.... you know?
So I myself went to a different type of source, one that looks at medical issues through the very real prism of economics.
https://www.forbes.com/sites/julianv.../#76ca2ca77161
I found a little "education", if you will, of my own:
"One example of this is in the UK, where doctors within the country’s national health system (the NHS) have in recent months have critiqued their experiences at the only clinic specialized in transgender medicine for children within the country. Last year, the governor of the Tavistock and Portman Foundation NHS Foundation Trust, Marcus Evans, accused the management of the clinic of having an “overvalued belief in” the expertise of its branch devoted to gender identity, the Gender Identity Development Service (GIDS). Evans further accused the trust of “dismiss[ing] challenge and examination.” Then this spring, five clinicians at the Tavistock Centre which is run by the Gender Identity Development Service (GIDS) allege that this center has been approving “life-changing medical intervention” on children and adolescents “without sufficient evidence of its long-term effects” citing feeling pressured to refer young people for life-altering treatments. There have been at least 18 staff members who have resigned in similar protest over the past three years from the GIDS. In response to these resignations, Carl Heneghan, director of the Centre of Evidence-based Medicine at the University of Oxford, told the Times: “Given paucity of evidence, the off-label use of drugs [for outcomes not covered by the medicine’s license] in gender dysphoria treatment largely means an unregulated live experiment on children.”
Earlier this month, Dr Kirsty Entwistle, a former clinician who worked at the Leeds’ GIDS, detailed how clinicians have been fearful around their work in diagnosing children for fear of being labelled “transphobic.” In her open letter to Polly Carmichael, the director of GIDS, Entwistle wrote:
I think it is a problem that GIDS clinicians are making decisions that will have a major impact on children and young people’s bodies and on their lives, potentially the rest of their lives, without a robust evidence base. GIDS clinicians tell children and families that puberty blockers/hormone blocks are “fully reversible” but the reality is no one knows what the impacts are on children’s brains so how is it possible to make this claim? It is also a problem that GIDS clinicians are afraid of raising their concerns for fear of being labelled transphobic by colleagues.
Echoing Entwistle’s assertions this week, Michael Biggs, an associate professor in the Department of Sociology at the University of Oxford, published “The Tavistock’s Experiment with Puberty Blockers” [1] where he analyzes the devastating reality behind GIDS’ treatment of children through the administration of puberty blockers (triptorelin). Biggs demonstrates how Carmichael vastly misrepresented the safety and efficacy of these puberty blockers and avoided publishing the results of a study which examined the use of puberty blockers on these very children. Biggs writes, “The failure to fully publish the results of the experiment—for all 44 children given triptorelin, on all the outcomes that the study measured—suggests that it was a pretext to administer unlicensed drugs rather than an attempt to acquire scientific knowledge.” Biggs shows the links between parent advocacy for the medicalization of their children and the suppression of the negative results of Carmichael’s study which she also misrepresented to the media. He also demonstrates the myriad financial conflicts of interest at the heart of this trust’s practices while maintaining that GIDS is carrying out experimental treatment on adolescents driven in large part by advocacy groups like Mermaids.
What we are facing today is a crisis in medicine and the biotech sector where the demand for treatments and medicines is often being advocated by the patient and patient advocacy groups who are emotionally invested in a certain outcome, regardless of safety or medical wisdom. While sympathy with those suffering from various conditions is warranted, we need to ensure that medical and research establishments are not hijacked by lobby groups who just want doctors to do as they command."
Bookmarks